Far out just read the question that is one hardcore no on Rem-L from the author. Seems to be focusing on the missed endpoints alot. Does the drawn target analogy have meaning in this context as we have found Rem-L to be effacious in the covid ARDS extension. Some rebuttal points that immediately come to mind are consistency and dosage has been improved since the original trials at Osiris? Or am I getting confused with another label in the MSB range.
Far out just read the question that is one hardcore no on Rem-L...
-
- There are more pages in this discussion • 12,640 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |